NewAmsterdam Pharma Company N.V. (NAMS) vs Precigen, Inc. (PGEN)
A side-by-side comparison of NewAmsterdam Pharma Company N.V. and Precigen, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NAMS
NewAmsterdam Pharma Company N.V.
$22.27HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PGEN
Precigen, Inc.
$7.55HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — NAMS vs PGEN
growth of $100 · dividends reinvested · last 6yNAMS +114.9% (+13.6%/yr)PGEN -11.0% (-1.9%/yr)NAMS compounded faster over this window
NAMS PGEN
NAMS vs PGEN: by the numbers
- •PGEN is the larger company ($2.69B vs $2.60B market cap).
- •Both run net losses; PGEN's is the smaller (-183.98% vs -3644.21% net margin).
Metrics side by side
Valuation
| Metric | NAMS | PGEN |
|---|---|---|
| Forward P/E | N/A | 44.06 |
| P/S ratio | 365.60 | 31.40 |
| P/B ratio | 4.12 | 61.77 |
Profitability
| Metric | NAMS | PGEN |
|---|---|---|
| Gross margin | 92.15% | 37.05% |
| Operating margin | -1002.90% | -1100.78% |
| Net margin | -3644.21% | -183.98% |
| ROE | -41.10% | -361.91% |
| ROIC | -38.70% | -28.02% |
Growth (annualized)
| Metric | NAMS | PGEN |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -21.26% |
| Total return CAGR (5Y) | 18.30% | 8.79% |
Frequently asked
- How have NAMS and PGEN total returns compared?
- Over the past 5 years, NAMS delivered 18.30% and PGEN delivered 8.79% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.